Dr Jennifer Munkley (Scientific Advisor) is the Lead Inventor of the GlycoScore test and was the driving force behind its discovery. She leads a prostate cancer research group at Newcastle University, and is Principal Investigator on numerous research studies. Jennifer has published over 20 scientific papers and has world leading expertise on the fundamental biology behind the GlycoScore biomarkers.
Jennifer earned a BSc in Biology from Durham University and a PhD in Cancer Genetics from the University of York.
Allan has over 25 years of international commercial and operational experience in the life science, diagnostics and medical devices field and has held senior (C-level/Board) positions in a number of companies. Most recently Allan served as Chief Operating Officer at QuantuMDx Group Limited and at Genedrive Plc., both point of care molecular diagnostic companies. Prior to that, as General Manager at Qiagen Manchester Ltd, he was responsible for Qiagen’s companion diagnostics operation, having previously held the position of Managing Director, at Gen-Probe Life Sciences Ltd.
Sandy has degrees from the University of Strathclyde, Scotland, and the University of California at Davis. He has spent over 40 years in senior management roles in the pharmaceutical, diagnostic and biotechnology industries. Currently he is Chairman of AMLo Biosciences and Newcells Biotech and was previously Chairman of Arquer Diagnostics and Non-Executive Director of Mologic.
Professor Heer is a Consultant Urologist surgeon and leads the Clinical and Translational Urology research group at Newcastle. A Key Opinion Leader in the Prostate Cancer field, he is a member of the National Cancer Research (NCRI) Prostate Group where he advises on prostate cancer clinical studies. Professor Heer’s research has a heavy clinical focus, and he has expertise in the design and running of Clinical Trials.
Sarah worked for Newcastle University in a number of roles before moving into the commercial world where she was recently employed as Chief Operating Officer at Biosignatures Ltd. She has extensive experience of project managing academic, clinical, and commercial research projects, and in the design and delivery of clinical trials. Sarah has experience of leading interdisciplinary, multi-site teams.
Rachel has recently completed her Biosciences PhD at Newcastle University and has previous experience in molecular genetics, stem cell research and cancer biology. She has expertise in experimental planning, assay development, and data management and analysis.
Gerald completed his Ph.D in cancer research at Newcastle University in 2019. Prior to joining GlycoScoreDx, Gerald undertook postdoctoral studies at Newcastle University and successfully completed the Innovate UK ICURe programme, outputs from which underpinned the early business planning for GlycoScoreDx. He has expertise in molecular diagnostics and is responsible for day-to-day management of the technical team.